NovoCurmin®

Overview

NovoCurmin® uses a matrix technology developed by İmuneks Farma and protected by multiple international patents. This technology addresses the solubility and bioavailability issues that limit the effective use of curcuminoids.

The patented technology uses only U.S. FDA GRAS-status and EFSA-approved food-grade excipients to form a matrix with curcumin.

It significantly enhances the solubility and bioavailability of turmeric extracts and is reported to achieve higher solubility and bioavailability than phytosomal and dextrin-based complexes. It offers higher Cmax and AUC values as well as efficient taste masking.

Applications

NovoCurmin® comes in a flexible format suitable for once-daily dosing.

It performs strongly both as a standalone ingredient and in synergistic combination formulations.

It is available in a range of forms.

Key features

It uses matrix technology protected by multiple international patents.

It is formulated only with FDA GRAS and EFSA-approved food-grade excipients.

It significantly improves the solubility of curcumin.

It is reported to deliver superior bioavailability compared to phytosomal and dextrin-based complexes.

It enhances absorption by achieving higher Cmax and AUC (area under the curve) values.

It offers efficient taste masking.

Mechanism of action

Curcuminoids are poorly soluble in water, which limits their absorption and, consequently, their bioavailability.

In NovoCurmin®, curcumin forms a patented matrix structure with food-grade excipients. This matrix significantly increases the solubility of curcumin, thereby enhancing its absorption.

As a result, higher Cmax and AUC values have been reported compared to phytosomal and dextrin-based complexes.